Delta insulin-like growth factor binding protein-1 (ΔIGFBP-1): A marker of hepatic insulin resistance?

Annals of Clinical Biochemistry

Volumn 51, Issue 2, 2014, Pages 269-276

  Borai, Anwar ^a,b   Livingstone, Callum ^c,d   Heald, Adrian H ^e   Oyindamola, Yusuf ^b   Ferns, Gordon ^f  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^e HOPE HOSPITAL   (United Kingdom)

^f BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

FSIVGTT; HOMA IR; IGFBP 1; insulin

Indexed keywords

FSIVGTT; HOMA-IR; IGFBP-1; INSULIN;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; LIVER; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TIME FACTORS;

EID: 84898680193     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213495818     Document Type: Article

References (24)

1. Turner NC,Clapham JC.Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities.Prog Drug Res. 1998;51:33-94.
2. Matthews DR,Hosker JP,Rudenski AS, et al.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia. 1985;28:412-419.
3. Ferrannini E,Mari A.How to measure insulin sensitivity.J Hypertens. 1998;16:895-906.
4. Borai A,Livingstone C,Ferns GA.The biochemical assessment of insulin resistance.Ann Clin Biochem. 2007;44:324-342.
5. Brismar K,Hall K.Clinical applications of IGFBP-1 and its regulation.Growth Regul. 1993;3:98-100.
6. Maddux BA,Chan A,Mandarino LJ, et al.IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance.Diabetes Care. 2006;29:1535-1537.
7. Heald AH,Cruickshank JK,Riste LK, et al.Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations.Diabetologia. 2001;44:333-339.
8. Borai A,Livingstone C,Zarif H, et al.Serum insulin-like growth factor binding protein-1: an improvement over other simple indices of insulin sensitivity in the assessment of subjects with normal glucose tolerance.Ann Clin Biochem. 2009;46:109-113.
9. Bergman RN.Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach.Diabetes. 1989;38:1512-1527.
10. Alberti KG,Zimmet PZ.Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.Diabet Med. 1998;15:539-553.
11. Borai A,Livingstone C,Kaddam I, et al.Selection of the appropriate method for the assessment of insulin resistance.BMC Med Res Methodol. 2011;11:158-158.
12. Conover CA,Lee PD,Kanaley JA, et al.Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans.J Clin Endocrinol Metab. 1992;74:1355-1360.
13. Lee PD,Conover CA,Powell DR.Regulation and function of insulin-like growth factor-binding protein-1.Proc Soc Exp Biol Med. 1993;204:4-29.
14. Borai A,Livingstone C,Mehta S, et al.Biological variation in fasting serum insulin-like growth factor binding protein-1 (IGFBP-1) among individuals with a varying glucose tolerance.Clin Biochem. 2009;42:1270-1274.
15. Boston RC,Stefanovski D,Moate PJ, et al.MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test.Diabetes Technol Ther. 2003;5:1003-1015.
16. Fossati P,Prencipe L,Berti G.Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine.Clin Chem. 1980;26:227-231.
17. Allain CC,Poon LS,Chan CS, et al.Enzymatic determination of total serum cholesterol.Clin Chem. 1974;20:470-475.
18. Warnick GR,Mayfield C,Benderson J, et al.HDL cholesterol quantitation by phosphotungstate-Mg2+ and by dextran sulfate-Mn2+-polyethylene glycol precipitation, both with enzymic cholesterol assay compared with the lipid research method.Am J Clin Pathol. 1982;78:718-723.
19. Fossati P,Prencipe L.Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.Clin Chem. 1982;28:2077-2080.
20. Friedewald WT,Levy RI,Fredrickson DS.Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin Chem. 1972;18:499-502.
21. Levy JC,Matthews DR,Hermans MP.Correct homeostasis model assessment (HOMA) evaluation uses the computer program.Diabetes Care. 1998;21:2191-2192.
22. Haffner SM,Miettinen H,Gaskill SP, et al.Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance.Diabetologia. 1996;39:1201-1207.
23. Matsuda M,DeFronzo RA.Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.Diabetes Care. 1999;22:1462-1470.
24. DeFronzo RA,Simonson D,Ferrannini E.Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus.Diabetologia. 1982;23:313-319.